Mangoceuticals, Inc. engages in developing, marketing, and selling men's wellness products and services via a telemedicine platform. The company is headquartered in Dallas, Texas. The company went IPO on 2023-03-21. The company is advancing its proprietary antiviral compound MGX-0024. The firm offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. The company has developed and is commercially marketing a brand of ED products under the brand name Mango; a brand of hair loss products under the brand name Grow; a brand of hormone balance and therapy products under the name Mojo, and a brand of weight loss products under the brand name Slim. Prime by MangoRx is a TRT product available by prescription. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin.
MGRX stock price ended at $0.42 on 星期一, after rising 2.44%
On the latest trading day May 11, 2026, the stock price of MGRX rose by 2.44%, climbing from $0.41 to $0.42. Throughout the session, the stock experienced a volatility of 12.20%, with prices fluctuating between a daily low of $0.41 and a high of $0.46. Alongside this price increase, trading volume also rose by 3.7M shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 702.9K shares were traded, amounting to a market value of approximately $7.1M.